Publications by authors named "Heidi Lane"

Claim this Profile
D
Discovery and optimization of oxidative phosphorylation inhibitors from a phenotypic screen.
Mahmoud El Shemerly, Florian Richalet, Dimitri Robay, Claude Nuoffer, Alexandra Kunz, Heidi A Lane

Anticancer Drugs· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.
Juanita Suzanne Lopez, Simon Haefliger, Ruth Plummer, Paul M Clement, Thomas R Jeffry Evans, Heidi Lane

Cell Rep Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual TTK/PLK1 inhibition has potent anticancer activity in TNBC as monotherapy and in combination.
Elisa Zanini, Nicole Forster-Gross, Felix Bachmann, Adrian Brüngger, Paul McSheehy, Heidi A Lane

Front Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma.
Matthias Holdhoff, Xiaobu Ye, Roy E Strowd, Burt Nabors, Tobias Walbert, Heidi A Lane

Neurooncol Adv· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models.
Mahmoud El Shemerly, Elisa Zanini, Marc Lecoultre, Paul R Walker, Laurenz Kellenberger, Heidi A Lane

Anticancer Drugs· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models.
Filippo Spriano, Luca Aresu, Luciano Cascione, Giorgia Risi, Alberto J Arribas, Heidi Lane

Am J Cancer Res· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The fibroblast growth factor receptor inhibitor, derazantinib, has strong efficacy in human gastric tumor models and synergizes with paclitaxel in vivo.
Paul M J McSheehy, Nicole Forster-Gross, Mahmoud El Shemerly, Felix Bachmann, Mila Roceri, Heidi A Lane

Anticancer Drugs· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study.
Markus Joerger, Thomas Hundsberger, Simon Haefliger, Roger von Moos, Andreas F Hottinger, Heidi Lane

Invest New Drugs· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin-a novel tumor checkpoint controller targeting microtubules.
Danielle M Burgenske, Surabhi Talele, Jenny L Pokorny, Ann C Mladek, Katrina K Bakken, Heidi A Lane

Neuro Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
Stephan Braun, Paul McSheehy, Karine Litherland, Phil McKernan, Nicole Forster-Gross, Heidi Lane

Expert Opin Investig Drugs· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Vassilis Genoud, Felipe I Espinoza, Eliana Marinari, Viviane Rochemont, Pierre-Yves Dietrich, Heidi A Lane

JCI Insight· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours.
Rebecca Kristeleit, Jeffry Evans, L Rhoda Molife, Nina Tunariu, Heather Shaw, Heidi A Lane

Br J Cancer· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.
Markus Joerger, Anastasios Stathis, Yannis Metaxas, Dagmar Hess, Mara Mantiero, Heidi Lane

Invest New Drugs· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study.
Beth Boulden Warren, Dianne Thornhill, Jill Stein, Michael Fadell, J David Ingram, Heidi D Lane

Blood Adv· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis.
Raphaël Bergès, Aurélie Tchoghandjian, Arnauld Sergé, Stéphane Honoré, Dominique Figarella-Branger, Heidi A Lane

Oncotarget· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
Don Benjamin, Dimitri Robay, Sravanth K Hindupur, Jens Pohlmann, Marco Colombi, Heidi A Lane

Cell Rep· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of circulating tumour cell clusters in human glioblastoma.
Ilona Krol, Francesc Castro-Giner, Martina Maurer, Sofia Gkountela, Barbara Maria Szczerba, Heidi Lane

Br J Cancer· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
Ashish Sharma, Angela Broggini-Tenzer, Van Vuong, Alessandra Messikommer, Katarzyna J Nytko, Heidi A Lane

Radiother Oncol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Syrosingopine sensitizes cancer cells to killing by metformin.
Don Benjamin, Marco Colombi, Sravanth K Hindupur, Charles Betz, Heidi A Lane

Sci Adv· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.
Raphaël Bergès, Aurélie Tchoghandjian, Stéphane Honoré, Marie-Anne Estève, Dominique Figarella-Branger, Heidi A Lane

Mol Cancer Ther· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Andrea E Prota, Franck Danel, Felix Bachmann, Katja Bargsten, Rubén M Buey, Heidi Lane

J Mol Biol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia.
Sweta Gupta, Azfar-E-Alam Siddiqi, J Michael Soucie, Marilyn Manco-Johnson, Roshni Kulkarni, Heidi Lane

Br J Haematol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Lesley-Ann Martin, Sunil Pancholi, Ian Farmer, Stephanie Guest, Ricardo Ribas, Heidi A Lane

Breast Cancer Res· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines.
Morven S Edwards, Heidi J Lane, Sharon L Hillier, Marcia A Rench, Carol J Baker

Vaccine· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research and innovation in the development of everolimus for oncology.
David Lebwohl, George Thomas, Heidi A Lane, Terence O'Reilly, Bernard Escudier

Expert Opin Drug Discov· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis